18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
ConditionPheochromocytoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital of Zhejiang University
About this trial
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 30-80 years old, primary school or above, with a regular caregiver;
Clinically diagnosed patients with pheochromocytoma;
Can provide informed consent, can understand and comply with the study requirements.
Disqualifiers
Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
Patients with mental disorders or primary affective disorders;
Unable to understand and adhere to the study protocol or provide informed consent;
Trial population
patients with suspected or confirmed pheochromocytoma
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
18F-MFBG
DrugPatients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Treatment groups
80 Participants
are divided into 1 treatment groupGroup A: 18F-MFBG PET/CT in Pheochromocytoma1 intervention
Trial outcomes
Primary outcomes
1
Correlation between positive and negative 18F-mFBG PET/CT or PET/MR Imaging and pathological diagnosis and treatment effect in patients with pheochromocytoma.
Main outcome measure
Time frame
through study completion, an average of 1 yearSecondary outcomes
1
False positive and false negative results of 18F-mFBG PET/CT or PET/MR Imaging in patients with pheochromocytoma.
Secondary outcome measure
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov